Lenvaxen is identified for this website as a product containing lenvatinib in stated 4 mg and 10 mg strengths. Product-specific manufacturer and authorization details require verification.
Lenvatinib is an oral multi-target receptor tyrosine kinase inhibitor used in several oncology indications.
Approved uses vary by country. U.S. labeling includes differentiated thyroid cancer, specified renal cell carcinoma combinations, unresectable hepatocellular carcinoma and selected endometrial carcinoma with pembrolizumab.
It inhibits several receptor tyrosine kinases, including VEGFR1–3, FGFR1–4, PDGFRα, KIT and RET.
Current U.S. LENVIMA labeling identifies 4 mg and 10 mg capsules.
The labeled regimens are generally once daily, but the prescribed dose depends on the indication and patient factors.
Current U.S. labeling allows administration with or without food.
If a missed dose cannot be taken within 12 hours, current U.S. labeling advises skipping it and taking the next dose at the regular time.
Important risks include hypertension, cardiac dysfunction, arterial thromboembolism, hepatotoxicity, renal impairment, proteinuria, diarrhea, bleeding, QT prolongation and other serious reactions.
Yes. Hypertension is a recognized and clinically important adverse reaction, and blood pressure should be monitored during treatment.
Eisai discovered and developed lenvatinib.
LENVIMA is the major reference brand for lenvatinib.
The products should not be described as identical solely because both contain lenvatinib. Product-specific formulation, manufacturer and authorization details must be established.
Lenvatinib is generally classified as a targeted anticancer therapy and receptor tyrosine kinase inhibitor rather than conventional cytotoxic chemotherapy.
Lenvatinib can cause embryo-fetal toxicity. Pregnancy considerations should be discussed with a healthcare professional.
Current U.S. labeling advises against breastfeeding during LENVIMA treatment.
Yes. Depending on the indication, monitoring can include blood pressure, liver and kidney function, urine protein, thyroid function and electrolytes.
Dose interruption and reduction are part of the management of certain adverse reactions. The appropriate adjustment depends on the toxicity and indication.